These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis. Burman J; Zjukovskaja C; Svenningsson A; Freyhult E; Wiberg A; Kultima K Brain Commun; 2023; 5(1):fcad011. PubMed ID: 36756308 [TBL] [Abstract][Full Text] [Related]
44. Intrathecal Rituximab as a Rescue Therapy in Refractory Pure CSF Positive, Non-Teratomatous Type Anti-NMDAR Encephalitis. Krishnan P; Thomas K Ann Indian Acad Neurol; 2022; 25(5):925-927. PubMed ID: 36561001 [TBL] [Abstract][Full Text] [Related]
45. Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment. Jayaraman S; Jayaraman A Front Neurol; 2022; 13():980758. PubMed ID: 36313502 [TBL] [Abstract][Full Text] [Related]
46. Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study. Alcalá C; Quintanilla-Bordás C; Gascón F; Sempere ÁP; Navarro L; Carcelén-Gadea M; Landete L; Mallada J; Cañizares E; Belenguer A; Carratalá S; Domínguez JA; Pérez-Miralles FC; Gil-Perotín S; Gasqué R; Cubas L; Castillo J; Casanova B J Neurol; 2022 Jul; 269(7):3676-3681. PubMed ID: 35107597 [TBL] [Abstract][Full Text] [Related]
48. Rituximab for people with multiple sclerosis. Filippini G; Kruja J; Del Giovane C Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215 [TBL] [Abstract][Full Text] [Related]
49. Can Systemic Anti-CD20 B Cell-Depleting Antibodies Eliminate Meningeal Follicles in Multiple Sclerosis? Gupta S; Zamvil SS Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34001659 [No Abstract] [Full Text] [Related]
50. A review of possible therapies for multiple sclerosis. Li H; Lian G; Wang G; Yin Q; Su Z Mol Cell Biochem; 2021 Sep; 476(9):3261-3270. PubMed ID: 33886059 [TBL] [Abstract][Full Text] [Related]
51. Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition. Bhargava P; Kim S; Reyes AA; Grenningloh R; Boschert U; Absinta M; Pardo C; Van Zijl P; Zhang J; Calabresi PA Brain; 2021 Jun; 144(5):1396-1408. PubMed ID: 33724342 [TBL] [Abstract][Full Text] [Related]
52. Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. Piehl F J Intern Med; 2021 Jun; 289(6):771-791. PubMed ID: 33258193 [TBL] [Abstract][Full Text] [Related]
53. Role of B Cells in Multiple Sclerosis and Related Disorders. Comi G; Bar-Or A; Lassmann H; Uccelli A; Hartung HP; Montalban X; Sørensen PS; Hohlfeld R; Hauser SL; Ann Neurol; 2021 Jan; 89(1):13-23. PubMed ID: 33091175 [TBL] [Abstract][Full Text] [Related]
54. Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension. Bergman J; Burman J; Bergenheim T; Svenningsson A J Neurol; 2021 Feb; 268(2):651-657. PubMed ID: 32901316 [TBL] [Abstract][Full Text] [Related]
55. Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS. Bergman J; Svenningsson A; Liv P; Bergenheim T; Burman J Fluids Barriers CNS; 2020 Jul; 17(1):49. PubMed ID: 32727487 [TBL] [Abstract][Full Text] [Related]
56. [Ocrelizumab for treatment of multiple sclerosis]. Graf J; Albrecht P; Goebels N; Aktas O; Hartung HP Nervenarzt; 2020 Aug; 91(8):722-734. PubMed ID: 32524163 [TBL] [Abstract][Full Text] [Related]
57. Neurofilaments in progressive multiple sclerosis: a systematic review. Williams T; Zetterberg H; Chataway J J Neurol; 2021 Sep; 268(9):3212-3222. PubMed ID: 32447549 [TBL] [Abstract][Full Text] [Related]